The last decade witnessed an exponential rise in the number of publications addressing management of sedation during critical illness. In 1998 Kollef and colleagues 1 suggested that the use of continuous infusions of sedatives may be associated with prolonged duration of mechanical ventilation and intensive care unit (ICU) stay. This was followed by a landmark study by Kress and colleagues 2 who demonstrated significant reduction in ventilation time and ICU stay with daily interruption of sedative infusions (DSI). Subsequent investigations have been consistent with the notion that strategies that reduce sedation depth such as algorithms and protocols for sedation management [3] [4] [5] and the use of validated sedation scales 6 can improve patient outcomes. This academic exuberance led to an endorsement of these strategies, and in particular DSI, by the UK Department of Health (www.cleansafe-care.nhs.uk), the Institute for Healthcare Improvement (www.IHI.org) and Safer Health Care Now! (www.saferhealthcarenow.ca).
In this issue of Anaesthesia and Intensive Care, a meta-analysis by Augustes and Ho 7 highlights the absence of adequate evidence for universal adoption of DSI without further evaluation. Their conclusions concur with those published in a critical review on the topic 8 in 2008. Pooled data from five DSI studies demonstrated lack of benefit of DSI on important clinical outcomes such as mortality (P=0.35) and ventilation time (P=0.66), and neatly demonstrate many of the limitations associated with sedation research in general and DSI studies in particular. None of the studies were blinded, most were single centre with a small sample size and significant heterogeneity amongst cohorts. Despite the limitations of this systematic review, the small number of studies included in the final analysis and the small total number (699) of patients involved, the need for external validation and further critical appraisal of the safety and practice of DSI is highlighted. Therefore, calls for DSI inclusion in standard practice are premature. While there is some evidence that incorporating DSI with other interventions may be synergistic 9 , there is no clear evidence of its impact on patient-centred outcomes such as delirium, post-traumatic stress disorder and cognitive function outside the context of North American intensive care practice. Nevertheless, a significant collateral benefit of the DSI concept is the recognition by intensive care clinicians of the risks associated with deep sedation. The need to critically evaluate sedation strategies including DSI should not invoke complacency in avoiding deep sedation when not clinically indicated. This is further highlighted in the same issue of the Journal by Oto and colleagues 10 who demonstrated that deep levels sedation don't equal 'sleep' in patients sedated with continuous infusion of midazolam. In a well conducted small randomised controlled trial, Oto and colleagues investigated the effect of daytime DSI in patients who were ventilated but deeply sedated (Ramsay score 4 to 5) on sleep pattern measured by polysomnography. Although it is not usual practice to keep patients so deeply sedated, most patients in the DSI group (less sedated) appeared to have longer periods of restorative sleep at night (slow wave and rapid eye movement sleep), while deeply sedated patients experienced almost none. The clinical significance of this difference deserves further investigation. The inverse relationship between cumulative midazolam dose and sleep quality, measured by the gold standard in sleep monitoring, shown in this study is remarkable. The practice of inducing night sedation should be discouraged and evaluated in light of these findings. Similarly, this reinforces the need to consider the impact of commonly used sedatives on sleep patterns in clinical practice and study design. Future research should focus on the relationship between sedative agents, sleep patterns and their impact on neurocognitive function and psychological recovery.
Australia and New Zealand researchers have examined the use of sedation algorithms and DSI in the context of Australian practice. These trials [11] [12] [13] failed to replicate the benefits seen in outcomes measured in previous studies. It is plausible that the Australia and New Zealand model of care (1:1 nurse: patient ratio, intensivists' led team and integrated care) is associated with frequent titration of sedative infusions, negating the need for sedation algorithms or DSI. Nevertheless, it would appear that our approach to maintaining patient comfort and safety Editorials Daily sedation interruption; a glass half empty? in Australia and New Zealand may still cause oversedation for some patients 14 .
There are many examples in critical care medicine where inadequately tested interventions are endorsed and included in practice guidelines. Intensive insulin therapy, medical emergency teams, early goal-directed therapy and extracorporeal respiratory support are amongst recent examples. DSI has been a cornerstone in bundles of care like Surviving Sepsis Campaign 15 and the ABCDE sedation and ventilation weaning bundle 16 .
Australian and New Zealand intensive care employs a model of care which contrasts with practice in North America and parts of Europe 17 . The impact of model of care may be most pronounced in sedation management and weaning from mechanical ventilation. This should be taken into consideration when translating research across contexts. International collaboration is therefore imperative to provide rigorous contributions to the evidence base regarding the management of patient comfort and safety.
It is a clinical and an economic necessity to evaluate ICU sedation practice and outcomes in a well designed adequately powered clinical trial. Describing and understanding current practice and its impact on patient outcomes in a longitudinal cohort study is a vital prelude to future research. This may identify candidate interventions to optimise modifiable elements of sedation practice, including sedative agents, depth of sedation and early recognition and management of agitation and delirium, in addition to many other nonpharmacologic interventions such as early mobilisation. These trials must address patientcentred, long-term outcomes such as mortality and cognitive function. However, conduct of research on this topic presents significant challenges. A pilot study assessing the feasibility of conducting a doubleblind randomised DSI trial in Australian ICUs demonstrated the enormous hurdles facing clinicians and carers 18 , and therefore, a co-ordinated well funded national approach is imperative.
The role and safety of DSI in improving outcomes from critical illness is still largely unknown. In the absence of well designed studies, recommendations can only be based on broad principles such as providing effective analgesia, using validated sedation and delirium scores and targeting the delivery of sedatives to light sedation with frequent titration of sedative agents. In the absence of a high level of evidence, it would seem that give less and assess more is the most reasonable approach. 
Y. Shehabi

